Economic implications of obesity among people with atherothrombotic disease

International Journal of Obesity

Volumn 34, Issue 8, 2010, Pages 1284-1292

  Ademi, Z ^a   Walls, H L ^a   Peeters, A ^a   Liew, D ^b   Hollingsworth, B ^a   Stevenson, C ^a   Steg, P G ^c   Bhatt, D L ^d   Reid, C M ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c INSERM   (France)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

atherothrombosis; direct health care costs; pharmaceuticals

Indexed keywords

AGED; AMBULATORY CARE; ARTICLE; ATHEROSCLEROSIS; AUSTRALIA; BODY MASS; BODY WEIGHT; CIGARETTE SMOKING; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG COST; EDUCATIONAL STATUS; FEMALE; GENERAL PRACTICE; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS;

AGED; ATHEROSCLEROSIS; AUSTRALIA; BODY MASS INDEX; CARDIOVASCULAR AGENTS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; OBESITY; PROSPECTIVE STUDIES; REGISTRIES;

EID: 77955471182     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2010.42     Document Type: Article

References (25)

1. Raebel MA, Malone DC, Conner DA, Xu S, Porter JA, Lanty FA. Health services use and health care costs of obese and nonobese individuals. Arch Intern Med 2004; 164: 2135-2140.
2. McCormick I, Stone I. Economic costs of obesity and the case for government intervention. Obes Rev 2007; 8 (Suppl 1): 161-164.
3. Thompson D, Brown J, Nichols G, Elmer P, Oster G. Body mass index and future healthcare costs: a retrospective cohort study. Obes Res 2001; 9: 210-218.
4. Thompson D, Wolf AM. The medical-care cost burden of obesity. Obes Rev 2001; 2: 189-197.
5. Quesenberry Jr CP, Caan B, Jacobson A. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med 1998; 158: 466-472.
6. Kuriyama S, Tsuji I, Ohkubo T, Anzai Y, Takahashi K, Watanabe Y et al. Medical care expenditure associated with body mass index in Japan: the Ohsaki Study. Int J Obes 2002; 26: 1069-1074.
7. Allender S, Rayner M. The burden of overweight and obesity-related ill health in the UK Sep. Obes Rev 2007; 8: 467-473. (Pubitemid 47283944)
8. Access Economics 2006. TheStudies Collaborat Economic Costs of Obesity. Report to Diabetes Australia. Available through: http://www.accesseconomics. com.au/publicationsreports/reports.php. (accessed 2 February 2009).
9. Narbro K, Agren G, Jonsson E, Naslund I, Sjostrom L, Peltonen M. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med 2002; 162: 2061-2069.
10. Finkelstein EA, Brown JB, Trogdon JG, Segel JE, Ben-Joseph RH. Age specific impact of obesity on prevalence and costs of diabetes and dyslipidemia. Value Health 2007; 10: S45-S51.
11. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS et al. The reduction of atherothrombosis for continued health (REACH) registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006; 151: 786, e1-e10.
12. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-189.
13. Reid C, Nelson MR, Shiel L, Chew D, Connor G, DeLooze F. Australians at risk: management of cardiovascular risk factors in the REACH Registry. Heart Lung Circ 2008; 17: 114-118.
14. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096.
15. Ademi Z, Liew D, Chew D, Conner G, Shiel L, Nelson MR et al. Drug treatment and cost of cardiovascular in Australia. Cardiovasc Ther 2009; 27: 164-172.
16. Chapko M, Liu C, Perkins M, Li Y, Fortney J, Maciejewski M. Equivalence of two healthcare costing methods: bottom-up and top-down. Health Econ 2008; 18: 1188-1201.
17. Pharmaceutical Benefits Schedule Item Reports. Period September 2006 to September 2007. Available from: https://www.medicareaustralia. gov.au/statistics/pbs-item.shtml. (accessed 2 February 2009).
18. Ademi Z, Liew D, Chew D, Conner G, Shiel L, Nelson MR et al. Predictors of annual pharmaceutical costs in Australia for participants with or at high risk of cardiovascular disease. Am J Cardiovasc Drugs 2010; 2: 1-10.
19. Duckett SJ. The Australian Health Care System, 3rd edn. Oxford University Press: South Melbourne, Victoria, 2007. Casemix view. http://www.sma.org.sg/ sma-news/3202/report.pdf (accessed 19 December 2009).
20. Duckett SJ. Casemix funding for acute hospital inpatient services in Australia. Med J Aust 1998; 169: S17-S21.
21. Medicare Benefits Schedule Book. Australian Government Department of Health and Ageing. November 2007. Available from: http://www.health.gov.au/ internet/mbsonline/publishing.nsf/Content/D25CFA71D62D2439CA2574F9002B42CD/ $File/2007-11-CLACP.pdf. (accessed 11 April 2009).
22. Medicare Australia. Available from: http://www.medicareaustralia. gov.au/. (accessed 11 April 2009).
23. Hauck K, Hollingsworth B. Do obese patients stay longer in hospital? Estimating the health care costs of obesity. Centre for Health Economics Research Paper 2008. Available through: http://www.buseco.monash.edu.au/centres/ che/pubs/rp028.pdf.
24. Senes S, Penm E. Australian Institute of Health and Welfare. Medicines for cardiovascular health: are they used appropriately? Cardiovascular disease series no. 27. Cat. no. 36. AIHW: Canberra, 2007.
25. Access Economics. The shifting burden of cardiovascular disease in Australia. National Heart Foundation of Australia: Canberra, 2005.